Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Performance of host blood transcriptomic signatures for diagnosing and predicting progression to tuberculosis disease in HIV-negative adults and adolescents: a systematic review protocol.

Mulenga H, Bunyasi EW, Mbandi SK, Mendelsohn SC, Kagina B, Penn-Nicholson A, Scriba T, Hatherill M.

BMJ Open. 2019 May 22;9(5):e026612. doi: 10.1136/bmjopen-2018-026612.

2.

Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.

Penn-Nicholson A, Hraha T, Thompson EG, Sterling D, Mbandi SK, Wall KM, Fisher M, Suliman S, Shankar S, Hanekom WA, Janjic N, Hatherill M, Kaufmann SHE, Sutherland J, Walzl G, De Groote MA, Ochsner U, Zak DE, Scriba TJ; ACS and GC6–74 cohort study groups.

PLoS Med. 2019 Apr 16;16(4):e1002781. doi: 10.1371/journal.pmed.1002781. eCollection 2019 Apr.

3.

Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases.

Guler R, Mpotje T, Ozturk M, Nono JK, Parihar SP, Chia JE, Abdel Aziz N, Hlaka L, Kumar S, Roy S, Penn-Nicholson A, Hanekom WA, Zak DE, Scriba TJ, Suzuki H, Brombacher F.

Mucosal Immunol. 2019 Mar;12(2):390-402. doi: 10.1038/s41385-018-0108-2. Epub 2018 Dec 12.

PMID:
30542107
4.

Meeting report: 5th Global Forum on TB Vaccines, 20-23 February 2018, New Delhi India.

Atmakuri K, Penn-Nicholson A, Tanner R, Dockrell HM.

Tuberculosis (Edinb). 2018 Dec;113:55-64. doi: 10.1016/j.tube.2018.08.013. Epub 2018 Aug 24.

5.

Author Correction: A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes.

Roy Chowdhury R, Vallania F, Yang Q, Lopez Angel CJ, Darboe F, Penn-Nicholson A, Rozot V, Nemes E, Malherbe ST, Ronacher K, Walzl G, Hanekom W, Davis MM, Winter J, Chen X, Scriba TJ, Khatri P, Chien YH.

Nature. 2018 Dec;564(7734):E5. doi: 10.1038/s41586-018-0635-8.

6.

A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes.

Roy Chowdhury R, Vallania F, Yang Q, Lopez Angel CJ, Darboe F, Penn-Nicholson A, Rozot V, Nemes E, Malherbe ST, Ronacher K, Walzl G, Hanekom W, Davis MM, Winter J, Chen X, Scriba TJ, Khatri P, Chien YH.

Nature. 2018 Aug;560(7720):644-648. doi: 10.1038/s41586-018-0439-x. Epub 2018 Aug 22. Erratum in: Nature. 2018 Dec;564(7734):E5.

7.

Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis.

Suliman S, Thompson E, Sutherland J, Weiner Rd J, Ota MOC, Shankar S, Penn-Nicholson A, Thiel B, Erasmus M, Maertzdorf J, Duffy FJ, Hill PC, Hughes EJ, Stanley K, Downing K, Fisher ML, Valvo J, Parida SK, van der Spuy G, Tromp G, Adetifa IMO, Donkor S, Howe R, Mayanja-Kizza H, Boom WH, Dockrell H, Ottenhoff THM, Hatherill M, Aderem A, Hanekom WA, Scriba TJ, Kaufmann SH, Zak DE, Walzl G; GC6-74 and ACS cohort study groups.

Am J Respir Crit Care Med. 2018 Apr 6. doi: 10.1164/rccm.201711-2340OC. [Epub ahead of print]

8.

Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.

Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, Vergara J, Mabwe S, Bilek N, Geldenhuys H, Luabeya AK, Ellis R, Ginsberg AM, Hanekom WA, Reed SG, Coler RN, Scriba TJ, Hatherill M; TBVPX-114 study team.

Lancet Respir Med. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-2600(18)30077-8.

PMID:
29595510
9.

Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention.

Fiore-Gartland A, Carpp LN, Naidoo K, Thompson E, Zak DE, Self S, Churchyard G, Walzl G, Penn-Nicholson A, Scriba TJ, Hatherill M.

Tuberculosis (Edinb). 2018 Mar;109:61-68. doi: 10.1016/j.tube.2017.11.009. Epub 2017 Nov 22.

10.

Diagnostic performance of an optimized transcriptomic signature of risk of tuberculosis in cryopreserved peripheral blood mononuclear cells.

Darboe F, Mbandi SK, Thompson EG, Fisher M, Rodo M, van Rooyen M, Filander E, Bilek N, Mabwe S, Hatherill M, Zak DE, Penn-Nicholson A, Scriba TJ; SATVI Clinical Immunology Team.

Tuberculosis (Edinb). 2018 Jan;108:124-126. doi: 10.1016/j.tube.2017.11.001. Epub 2017 Nov 6. No abstract available.

PMID:
29523312
11.

Protein kinase C-delta (PKCδ), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice.

Parihar SP, Ozturk M, Marakalala MJ, Loots DT, Hurdayal R, Beukes D, Van Reenen M, Zak DE, Mbandi SK, Darboe F, Penn-Nicholson A, Hanekom WA, Leitges M, Scriba TJ, Guler R, Brombacher F.

Mucosal Immunol. 2018 Mar;11(2):579-580. doi: 10.1038/mi.2017.108. Epub 2017 Dec 20.

PMID:
29346346
12.

Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease.

Scriba TJ, Penn-Nicholson A, Shankar S, Hraha T, Thompson EG, Sterling D, Nemes E, Darboe F, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Johnson JL, Boom WH, Hatherill M, Valvo J, De Groote MA, Ochsner UA, Aderem A, Hanekom WA, Zak DE; other members of the ACS cohort study team.

PLoS Pathog. 2017 Nov 16;13(11):e1006687. doi: 10.1371/journal.ppat.1006687. eCollection 2017 Nov.

13.

Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population.

Baguma R, Penn-Nicholson A, Smit E, Erasmus M, Day J, Makhethe L, de Kock M, Hughes EJ, van Rooyen M, Pienaar B, Stone L, Hanekom W, Brennan MJ, Wallis RS, Hatherill M, Scriba TJ.

PLoS One. 2017 Sep 8;12(9):e0184563. doi: 10.1371/journal.pone.0184563. eCollection 2017.

14.

Protein kinase C-delta (PKCδ), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice.

Parihar SP, Ozturk M, Marakalala MJ, Loots DT, Hurdayal R, Maasdorp DB, Van Reenen M, Zak DE, Darboe F, Penn-Nicholson A, Hanekom WA, Leitges M, Scriba TJ, Guler R, Brombacher F.

Mucosal Immunol. 2018 Mar;11(2):496-511. doi: 10.1038/mi.2017.68. Epub 2017 Aug 9. Erratum in: Mucosal Immunol. 2017 Dec 20;:.

PMID:
28832027
15.

Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania.

Amelio P, Portevin D, Reither K, Mhimbira F, Mpina M, Tumbo A, Nickel B, Marti H, Knopp S, Ding S, Penn-Nicholson A, Darboe F, Ohmiti K, Scriba TJ, Pantaleo G, Daubenberger C, Perreau M.

PLoS Negl Trop Dis. 2017 Jul 31;11(7):e0005817. doi: 10.1371/journal.pntd.0005817. eCollection 2017 Jul.

16.

The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010-2014.

Brennan MJ, Tanner R, Morris S, Scriba TJ, Achkar JM, Zelmer A, Hokey DA, Izzo A, Sharpe S, Williams A, Penn-Nicholson A, Erasmus M, Stylianou E, Hoft DF, McShane H, Fletcher HA.

Clin Vaccine Immunol. 2017 Sep 5;24(9). pii: e00142-17. doi: 10.1128/CVI.00142-17. Print 2017 Sep. Review.

17.

Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis.

Moguche AO, Musvosvi M, Penn-Nicholson A, Plumlee CR, Mearns H, Geldenhuys H, Smit E, Abrahams D, Rozot V, Dintwe O, Hoff ST, Kromann I, Ruhwald M, Bang P, Larson RP, Shafiani S, Ma S, Sherman DR, Sette A, Lindestam Arlehamn CS, McKinney DM, Maecker H, Hanekom WA, Hatherill M, Andersen P, Scriba TJ, Urdahl KB.

Cell Host Microbe. 2017 Jun 14;21(6):695-706.e5. doi: 10.1016/j.chom.2017.05.012.

18.

A novel blood test for tuberculosis prevention and treatment.

Penn-Nicholson A, Scriba TJ, Hatherill M, White RG, Sumner T.

S Afr Med J. 2016 Dec 21;107(1):4-5. doi: 10.7196/SAMJ.2016.v107.i1.12230. No abstract available.

19.

Predicting tuberculosis risk - Authors' reply.

Zak D, Scriba TJ, Hatherill M, Penn-Nicholson A, Hanekom W.

Lancet. 2016 Nov 5;388(10057):2233-2234. doi: 10.1016/S0140-6736(16)31653-1. No abstract available.

PMID:
27825498
20.

Epidemiologic studies and novel clinical research approaches that impact TB vaccine development.

Evans TG, Churchyard GJ, Penn-Nicholson A, Chen C, Gao X, Tait DR, Hatherill M.

Tuberculosis (Edinb). 2016 Aug;99 Suppl 1:S21-5. doi: 10.1016/j.tube.2016.05.008. Epub 2016 Jun 11.

21.

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants.

Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H.

Nat Commun. 2016 May 6;7:11633. doi: 10.1038/ncomms11633. No abstract available.

22.

T-cell activation is an immune correlate of risk in BCG vaccinated infants.

Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H.

Nat Commun. 2016 Apr 12;7:11290. doi: 10.1038/ncomms11290. Erratum in: Nat Commun. 2016 May 06;7:11633.

23.

A blood RNA signature for tuberculosis disease risk: a prospective cohort study.

Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Hussey GD, Abrahams D, Kafaar F, Hawkridge T, Verver S, Hughes EJ, Ota M, Sutherland J, Howe R, Dockrell HM, Boom WH, Thiel B, Ottenhoff THM, Mayanja-Kizza H, Crampin AC, Downing K, Hatherill M, Valvo J, Shankar S, Parida SK, Kaufmann SHE, Walzl G, Aderem A, Hanekom WA; ACS and GC6-74 cohort study groups.

Lancet. 2016 Jun 4;387(10035):2312-2322. doi: 10.1016/S0140-6736(15)01316-1. Epub 2016 Mar 24.

24.

Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.

Penn-Nicholson A, Geldenhuys H, Burny W, van der Most R, Day CL, Jongert E, Moris P, Hatherill M, Ofori-Anyinam O, Hanekom W; Vaccine Study Team, Bollaerts A, Demoitie MA, Kany Luabeya AK, De Ruymaeker E, Tameris M, Lapierre D, Scriba TJ.

Vaccine. 2015 Jul 31;33(32):4025-34. doi: 10.1016/j.vaccine.2015.05.088. Epub 2015 Jun 10.

25.

Mycobacterium tuberculosis-specific CD4 T cells are the principal source of IFN-γ in QuantiFERON assays in healthy persons.

Penn-Nicholson A, Nemes E, Hanekom WA, Hatherill M, Scriba TJ.

Tuberculosis (Edinb). 2015 May;95(3):350-1. doi: 10.1016/j.tube.2015.03.002. Epub 2015 Mar 10. No abstract available.

PMID:
25802032
26.

Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry.

Kagina BM, Mansoor N, Kpamegan EP, Penn-Nicholson A, Nemes E, Smit E, Gelderbloem S, Soares AP, Abel B, Keyser A, Sidibana M, Hughes JE, Kaplan G, Hussey GD, Hanekom WA, Scriba TJ.

J Immunol Methods. 2015 Feb;417:22-33. doi: 10.1016/j.jim.2014.12.003. Epub 2014 Dec 16.

27.

Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.

Qin Y, Banasik M, Kim S, Penn-Nicholson A, Habte HH, LaBranche C, Montefiori DC, Wang C, Cho MW.

Virology. 2014 Aug;462-463:363-76. doi: 10.1016/j.virol.2014.06.006.

28.

A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis.

Wang D, Suhrbier A, Penn-Nicholson A, Woraratanadharm J, Gardner J, Luo M, Le TT, Anraku I, Sakalian M, Einfeld D, Dong JY.

Vaccine. 2011 Mar 24;29(15):2803-9. doi: 10.1016/j.vaccine.2011.01.108. Epub 2011 Feb 12.

29.

A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.

Holman DH, Penn-Nicholson A, Wang D, Woraratanadharm J, Harr MK, Luo M, Maher EM, Holbrook MR, Dong JY.

Clin Vaccine Immunol. 2009 Nov;16(11):1624-32. doi: 10.1128/CVI.00182-09. Epub 2009 Sep 23.

30.

Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope.

Penn-Nicholson A, Han DP, Kim SJ, Park H, Ansari R, Montefiori DC, Cho MW.

Virology. 2008 Mar 15;372(2):442-56. Epub 2007 Dec 19.

31.

Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruption.

Lederman MM, Penn-Nicholson A, Stone SF, Sieg SF, Rodriguez B.

Curr Opin HIV AIDS. 2007 Jan;2(1):56-61. doi: 10.1097/COH.0b013e3280119264.

PMID:
19372866
32.

Biology of CCR5 and its role in HIV infection and treatment.

Lederman MM, Penn-Nicholson A, Cho M, Mosier D.

JAMA. 2006 Aug 16;296(7):815-26. Review.

PMID:
16905787
33.

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor.

Han DP, Penn-Nicholson A, Cho MW.

Virology. 2006 Jun 20;350(1):15-25. Epub 2006 Feb 28.

34.

Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C.

Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, Quiñones-Mateu ME, Penn-Nicholson A, Murray M, Richard N, Lobritz M, Zimmerman PA, Kawamura T, Blauvelt A, Arts EJ.

J Virol. 2003 Jan;77(2):1021-38.

Supplemental Content

Loading ...
Support Center